This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

D-2939CIPCONDIV4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT

In the application of: Williams et al) Group Art Unit: N/A (Prior App.: 1648)
Serial No. N/A	Examiner: N/A
Filing Date: HEREWITH) (Prior App.: Li, Bao Q.
For: SOLUBLE RECOMBINANT BOTULINUM TOXIN PROTEINS)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

Dear Sir:

Applicant wishes to call to the attention of the Examiner the documents cited on the accompanying Form PTO-1449. No concession is made that these documents are prior art, and applicant expressly reserves the right to antedate the documents as may be appropriate. Applicant requests that each of these documents be made of record in the above-identified application.

All of these documents were cited in related Application Serial No. 08/405,496, filed March 16, 1995 and Application Serial No. 08/704,159, filed August 28, 1996.

Therefore, no copies of these documents are submitted herewith.

Respectfully submitted,

Frank J. Xxa

Attorney for Applicant

Reg. No. 25,612

4 Venture, Suite 300 Irvine, CA 92618

(949) 450-1750 Facsimile (949) 450-1764

FJUxa/ac

ORM PTO-1449 fodified)

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No. 3-2434CJRCD

Serial No .:

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)

Applicant: James A. Williams et al.

orné 10	O/L\\	(Use Several Sheets	If Necessary)		Filing Date:	herewith	-	Group Art Un	it;		
7 CFR § 1.9	0(0))			U.S. PATENT DOC							
xaminer Initials		Serial / Patent Number	Issue Date	Applic	ant / Patentee	С	lass	Subclass	Filing Date		
	l	5,080,895	1/14/92	·	Tokoro			<u>.</u>			
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)											
	2	Cato et al. (1986) "Clostridium," in Bergey's Manual® of Systematic Bacteriology, 2:1141-1200, Sneath (ed.), Williams & Wilkins									
	3	Engelkirk et al. (1992) "Classification," in Principles and Practice of Clinical Anaerobic Bacteriology, pp. 22-23, Star Publishing Co., Belmont, CA									
	. 4	Stephen and Pietrowski (1986) "Toxins Which Traverse Membranes and Deregulate Cells," in Bacterial Toxins, 2d ed., pp. 66-67, American Society for Microbiology									
	· 5	Berkow and Fletcher (eds.) (1992) "Bacterial Diseases," in Merck Manual of Diagnosis and Therapy, 16th ed., pp. 116-126, Merck Research Laboratories, Rahway, N.J.									
	6	Sigmund and Fraser (eds.) (1979) "Clostridial Infections," in Merck Veterinary Manual, 5th ed., pp. 396-409, Merck & Co., Rahway, NJ.									
	7		Hatheway (1990) "Bacteriophages and plasmids and their roles in coding for botulinal neurotoxins," Clin. Microbiol. Rev. 3:73-74								
	8	Arnon (1986) "Infa	nt Botulism: Anticipa	ting the Second Dec	ade," J. Infect. I	ois. 154:201-206					
	9	Arnon (1980) "Infa	nt Botulism," Алп. Re	v. Med. 31:541-559	<u> </u>						
	10	MacDonald et al. (1986) "The Changing	Epidemiology of A	dult Botulism in 1	the United States,	Am. J.	Epidemiol. 124:	794-799		
	11	1 798) "Equine Antitoxin U								
	12	Swartz (1990) "An Lippincott Co.	Swartz (1990) "Anaerobic Spore-Forming Bacilli: The Clostridia," in B.D. Microbiology, 4th edition, pp. 633-646, Davis et al.(eds.), J.B. Lippincott Co.								
	13		tulismus durch Inhalat								
	14	Franz et al. (1993)	in Botulinum and Tel	anus Neurotoxins,	pp. 473-476, B.R	DasGupta, ed.,	Plenum F	Press, NY			
	15	Amon et al. (1981) "Infant Botulism: E	pidemiology and Re	lation to Sudden	Infant Death Syn	drome,"	Epidemiol. Rev.	3:45-66		
	16	Frankovich and A	non (1991) "Clinical	Trial of Botulism In	nmune Globulin	for Infant Botulist	n," West	J. Med. 154:10	3		
	17		Clostridium botulinum						·		
	18	Balady (1991) *Bo	tulism Antitoxin Field	led for Operation De	esert Storm," USA	AMRDC Newslett	er, p. 6				
	19	Schwarz and Arnon (1992) "Botulism Immune Globulin for Infant Botulism Arrives-One Year and A Gulf War Later," Western J. Med. 156:197-198									
	20	Peterson et al. (19	79) "The Sudden Infa	nt Death Syndrome	and Infant Botuli	sm," Rev. Infect.	Dis. 1:63	30-634			
	21	Arnon et al. (1978) *Intestinal Infection and Toxin Production by Clostridium Botulinum as One Cause of Sudden Infant Death Syndrome Lancet, pp. 1273-1277									
	22	Informational Brochure for the Pentavalent (ABCDE) Botulinum Toxoid, Centers for Disease Control, Rév. 1995, pp. 1-3 and 3 unnumbered pages Brooks et al. (eds.) (1991) "Infections Caused by Anaerobic Bacteria," in Jawetz, Melnick, & Adelberg's Medical Microbiology, 19th ed., pp. 257-262, Appleton & Lange, San Mateo, CA									
	23										
	24	Engelkirk et al. (1992) Principles and Practice of Clinical Anaerobic Bacteriology, pp. 64-67, Star Publishing Co., Belmont, CA Lyerly et al. (1992) "Characterization of a Toxin A-Negative, Toxin B-Positive Strain of Clostridium difficile," Infect. Immun. 60:4633-							mont, CA		
	25								Immun. 60:4633-463		
	26	Borriello et al. (1	990) "Virulence Facto	rs of Clostridium dij	fficile," Rev. Infe	ct. Dis., 12(Suppl	. 2):S185	i-S191			
	27	Borriello et al. (1990) "Virulence Factors of Clostridium difficile," Rev. Infect. Dis., 12(Suppl. 2):S185-S191 Lyerly et al. (1985) "Effects of Clostridium difficile Toxins Given Intragastrically to Animals," Infect. Immun. 47:349-352									
					Date Consid						
xaminer:		itial situation consider	red. Draw line throug	h citation if not in c	conformance and	not considered. I	nclude c	opy of this form			

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy with next communication to applicant.

FORM PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office Attorney Docket No.: 172139CIP(D) Serial No.: 100

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)

with next communication to applicant.

Applicant: James A. Williams et al.

27 CED \$ 1 09/b))

Filing Date: New With

Group Art Unit:

(37 CFR § 1.98(b))	Filing Date: New With Group Art Unit:								
	OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)								
28	Rolfe (1990) "Binding Kinetics of Clostridium difficile Toxins A and B to Intestinal Brush Border Membrane: from Infant and Adult Hamsters," Infect. Immun. 59:1223-1230								
29	Kim and Rolfe (1987) "The Protective Role of Antibody to Toxin A in Clostridium difficile - Induced Reocecitis, "Abstr. Ann. Meet Am. Soc. Microbiol. 69:62								
30	Banno et al. (1984) "Biochemical Characterization and Biologic Actions of Two Toxins (D-1 and D-2) From Clostridium difficile," Rev. Infect. Dis. 6(Suppl. 1:S11-S20)								
31	Rihn et al. (1984) "A New Purification Procedure for Clostridium difficile Enterotoxin," Biochem. Biophys. Res. Comm. 124:690-695								
32	Justus et al. (1982) "Myoelectric Effects of Clostridium difficile: Motility-Altering Factors Distinct From its Cytotoxin and Enterotoxin in Rabbits," Gastroenterol. 83:836-843								
33	Finegold et al. (1992) "Antimicrobial-Associated Pseudomembranous Colitis," in Clinical Guide to Anaerobic Infections, pp. 88-89, Star Publishing Co., Belmont, CA								
34	United States Pharmacopeia (1990) United States Pharmacopeial Convention, Vol. XXII:1515-1516 Rockville, MD								
35	FDA Guidelines for Parenteral Drugs (December 1987) i.e., Guideline on Validation of the Limulus Amebocyte Lysate Test as an End- Product Endotoxin Test for Human and Animal Parenteral Drugs, Biological Products and Medical Devices								
. 36	Pearson (1985) "Equivalency of LAL and USP Rabbit Pyrogen Tests," in Pyrogens: endotoxins, lal testing and depyrogenation, Marcel Dekker, NY, pp. 150-155								
. 37	Minton (1995) "Molecular Genetics of Clostridial Neurotoxins," Curr. Top. Microbiol. Immunol. 195:161-194								
38	Benedict and Yamaga (1966) "Immunoglobulins and Antibody Production in Avian Species," in Comparative Immunology, pp. 335-375 (J.J. Marchaloni, ed.), Blackwell, Oxford								
39	Patterson et al. (1962) "Antibody Production and Transfer to Egg Yolk in Chickens," Immunol. 89:272-278								
40	Carroll and Stollar (1983) "Antibodies of Calf Thymus RNA Polymerase II from Egg Yolks of Immunized Hens," J. Biol. Chem. 258:24-26								
- 41	Polson et al. (1980) "Antibodies to Proteins from Yolk of Immunized Hens," Immunol. Comm. 9:495-514								
42	DasGupta and Sugiyama (1972) "A Common Subunit Structure In Clostridium Botulinum Type A, B, and E Toxins, "Biochem. Biophys. Res. Commun. 48:108-112								
43	DasGupta (1990) "Structure and Biological Activity of Botulinum Neurotoxin," J. Physiol. 84:220-228								
44	Halpern and Loftus (1993) "Characterization of the Receptor-binding Domain of Tetanus Toxin," J. Biol. Chem. 268:11188-11192								
45	Whelan et al. (1992) "Molecular Cloning of the Clostridium botulinum Structural Gene Encoding the Type B Neurotoxin and Determination of its Entire Nucleotide Sequence," Appl. Environ. Microbiol. 58:2345-2354								
46	Sakaguchi (1983) "Clostridium Botulinum Toxins," Pharmac. Ther. 19:165-194								
47	Moberg and H. Sugiyama (1978) "Affinity Chromatography Purification of Type A Botulinum Neurotoxin from Crystalline Toxic Complex,"Appl. Environ. Microbiol. 35:878-880								
48	Thalley et al. (1993) "Development of an Avian Antitoxin to Type A Botulinum Neurotoxin," in Botulinum and Tetanus Neurotoxins, pp. 467-472, B.R. DasGupta, ed., Plenum Press, NY								
. 49	Schantz and Johnson (1992) "Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine," Microbiol. Rev. 56:80-99								
50	Makoff et al. (1989) "Expression of Tetanus Toxin Fragment C in E. Coli: Its Purification and Potential Use as a Vaccine," Bio/Technology 7:1043-1046								
51	Makoff et al. (1989) "Expression of tetanus toxin fragment C in E. coli: high level expression by removing rare codons," Nucl. Acids Res 17:10191-10202								
	Date Considered:								

U.S. Department of Commèrce Patent and Trademark Office

Attorney Docket No.: 1-2439 (1911) שועב

Serial No .: MA

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)

Applicant: James A. Williams et al.

Group Art Unit: Filing Date: MANUALY (37 CFR § 1.98(b)) OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication) Halpern et al. (1990) "Cloning and Expression of Functional Fragment C of Tetanus Toxin," Infect. Immun. 58:1004-1009 52 Romanos et al. (1991) "Expression of tetanus toxin fragment C in yeast: gene synthesis is required to elimina e fortuitous polyadenylation sites in AT-rich DNA," Nucleic Acids Res. 19:1461-1467 53 Charles et al. (1991) "Synthesis of Tetanus Toxin Fragment C in Insect Cells by Use of a Baculovirus Expression System," Infect. Immun. 54 59:1627-1632 Popoff et al. (1991) "Characterization of the C3 Gene of Clostridium botulinum Types C and D and Its Expression in Escherichia coli," 55 Infect Immun. 59:3673-3679 LaPenotiere et al. (1993) "Development of a Molecular Engeineered Vaccine for C. Botulinum Neurotoxins," in Botulinum and Tetanus Neurotoxins, B.R. DasGupta, ed., Plenum Press, NY, pp. 463-466 56 Thompson et al. (1990) The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence 57 analysis of the encoding gene," Eur. J. Biochem. 189:73-81 LaPenotiere et al. (1995) "Expression of a Large, Nontoxic Fragment of Botulinum Neurotoxin Serotype A and Its Use as an Immunogen," 58 Toxicon. 33:1383-1386 Middlebrook and Brown (1995) "Immunodiagnosis and Immunotherapy of Tetanus and Botulinum Neurotoxins," Curr. Top. Microbiol. 59 Immunol. 195:89-122 Hutson et al. (1994) "Nucleotide Sequence of the Gene Coding for Non-Proteolytic Clostridium botulinum Type B Neurotoxin: Comparison with Other Clostridial Neurotoxins," Curr. Microbiol. 28:101-110 60 Poulet et al. (1992) "Sequences of the Botulinal Neurotoxin E Derived from Clostridium Botulinum Type E (Strain Beluga) and Clostridium Butyricum (Strains ATCC 43181 and ATCC 43755)," Biochem. Biophys. Res. Commun. 183:107-113 61 Whelan et al. (1992) "The complete amino acid sequence of the Clostridium botulinum type-E neurotoxin, derived by nucleotide-sequence analysis of the encoding gene," Eur. J. Biochem. 204:657-667 62 Fujii et al. (1993) "The complete nucleotide sequence of the gene encoding the nontoxic component of Clostridium botulinum type E 63 progenitor toxin, J. Gen. Microbiol. 139:79-86 Delmee et al. (1990) "Characterization of Flagells of Clostridium difficile and Their Role in Serogrouping Reactions," J. Clin. Microbiol. 64 28:2210-2214 Delmee and Avesani (1990) "Virulence of ten serogroups of Clostridium difficile in hamsters," J. Med Microbiol. 33:85-90 65 Toma et al. (1988) "Serotyping of Clostridium difficile," J. Clin. Microbiol. 26:426-428 66 Delmee et al. (1985) "Serogrouping of Clostridium difficile Strains by Slide Agglutination," J. Clin. Microbiol. 21:323-327 67 Davies and Borriello (1990) "Detection of Capsule in Strains of Clostridium difficile of Varying Virulence and Toxigenicity," Microbial 68 Path. 9:141-146 Edelstein (1990) "Processing Clinical Specimens for Anaerobic Bacteria: Isolation and Identification Procedures," in Bailey and Scott's Diagnostic Microbiology, pp. 477-507, C.V. Mosby Co. Baron and Finegold (eds.) 69 Padhye et al. (1990) "Production and Charanterization of a Monoclonal Antibody Specific for Enterohemorrhagic Escherichia coli of Serotypes 0157:H7 and 026:H11," J. Clin. Microbiol. 29:99-103 70 Lyerly et al. (1991) "Passive Immunization of Hamsters Against Disease Caused by Clostridium difficile by Use of Bovine Immunoglobulin 71 G Concentrate," Infect. Immun. 59:2215-2218 DasGupta & Sathyamoorthy (1984) *Purification and Amino Acid Composition of Type A Botulinum Neurotoxin, Toxicon, 22:415-424 72 Singh & DasGupta (1989) "Molecular Differences Between Type A Botulinum Neurotoxin and Its Toxoid," Toxicon 27:403-410 73 Date Considered: Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form EXAMINER: with next communication to applicant.

U.S. Department of Commerce **FORM PTO-1449** Attorney Docket No.: 1-2939CIPCON Serial No.: Patent and Trademark Office 'Modified) DIVY INFORMATION DISCLOSURE STATEMENT BY APPLICANT Applicant: James A. Williams et al. (Use Several Sheets If Necessary) NENCULARIN Filing Date: Group Art Unit: 37 CFR § 1.98(b)) OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication) Towbin et al. (1979) "Electrophoretic Transfer of Proteins from Polyacrylamide Gels to Nitrocellulose Sheets: Procedure and Some 74 Applications, "Proc. Natl. Acad. Sci. USA, 76:4350-4354 Weber and Osborn (1975) "Proteins and Sodium Dodecyl Sulfate: Molecular Weight Determination on Polyacrylamide Gels and Related 75 Procedures," in The Proteins, pp. 179-223, 3d Edition (H. Neurath & R.L. Hill, eds), Academic Press, NY Carroll and Laughon (1987) "Production and purification of polyclonal antibodies to the foreign segment of β-galactosidase fusion proteins," 76 in DNA Cloning: A Practical Approach, Vol.III, pp. 89-111, D. Glover (ed.) IRL Press, Oxford Thalley and Carroll (1990) "Rattlesnake and Scorpion Antivenoms From The Egg Yolks of Immunized Hens," Bio/Technology 8:934-938 77 Ohishi et al. (1977) "Oral Toxicities of Clostridium botulinum Toxins in Response to Molecular Size," Infect. Immun. 16:106-107 78 Wren et al. (1991) "Antigenic Cross-Reactivity and Functional Inhibition by Antibodies to Clostridium difficile Toxin A, Streptococcus 79 mutans Glucan-Binding Protein, and a Synthetic Peptide," Infect. Immun. 59:3151-3155 Ehrich et al. (1980) "Production of Clostridium difficile Antitoxin," Infect. Immun. 28:1041-1043 80 McGee et al. (1992) "Local induction of tumor necrosis factor as a molecular mechanism of mucosal damage by gonococci," Microb. Path. 81 12:333-341 Fekety (1986) "Animal Models of Antibiotic-Induced Colitis," in Experimental Models in Antimicrobial Chemotherapy, 2:61-72, Zak and 82 Sande (eds.), Harcourt Brace Jovanovich, NY Borriello et al. (1987) "Clostridium difficile-a spectrum of virulence and analysis of putative virulence determinants in the hamster model of 83 antibiotic-associated colitis," J. Med. Microbiol. 24:53-64 Kim et al. (1987) "Immunization of Adult Hamsters Against Clostridium difficile-Associated Ileocecitis and Transfer of Protection to Infant Hamsters," Infect. Immun. 55:2984-2992 84 Borriello et al. (1988) "Mucosal Association by Clostridium difficile in the hamster gastrointestinal tract," J. Med. Microbiol. 25:191-196 85 Dove et al. (1990) "Molecular Characterization of the Clostridium difficile Toxin A Gene," Infect. Immun. 58:480-488 86 Williams et al. (1995) "Expression of foreign proteins in E. coli using plasmid vectors and purification of specific polyclonal antibodies," in DNA Cloning 2: Expression Systems, pp. 15-58, Glover and Hames (eds.) IRL Press, Oxford 87 von Eichel-Streiber and Sauerborn (1990) "Clostridium difficile Toxin A Carries a C-Terminal Repetitive Structure Homologous to the 88 Carbohydrate Binding Region of Streptococcal Glycosyltransferases," Gene 96:107-113 Wren and Tabaqchali (1987) "Restriction Endonuclease DNA Analysis of Clostridium difficile," J. Clin. Microbiol. 25:2402-2404 RQ Price et al. (1987) "Cloning of the Carbohydrate-binding Portion of the Toxin A Gene of Clostridium difficile," Curr. Microbiol. 16:55-60 90 Krivan et. al. (1986) "Cell Surface Binding Site for Clostridium difficile Enterotoxin: Evidence for a Glycoconjugate Containing the 91 Sequence Gala 1-3 Gal Bl-4 GleNAc, Infect. Immun., 53:573-581 von Eichel-Streiber et al. (1989) "Cloning and Characterization of Overlapping DNA Fragments of the Toxin A Gene of Clostridium 92 difficile," J. Gen. Microbiol. 135:55-64 yerly et al. (1989) "Nonspecific Binding of Mouse Monoclonal Antibodies to Clostridium difficile Toxins A and B,"Curr. Microbiol. 93 Lyerly et al. (1990) "Vaccination Against Lethal Clostridium difficile Enterocolitis with a Nontoxic Recombinant Peptide of Toxin A," Curr. 94 Microbiol. 21:29-32 Swanson et al. (1991) "In Vitro and In Vivo Evaluation of Tiacumcins B and C Against Clostridium difficile," Antimicro. Agents and Chemo. Q5 Swanson et al. (1989) "Phenelfamycins, a Novel Complex of Elfamycin-type Antibiotics, III. Activity In Vitro and in a Hamster Colitis 96 Model," J. Antibiotics 42:94-101 Date Considered: Examiner:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form

EXAMINER:

with next communication to applicant.

FORM PTO-14- (Modified)	19	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: 5-21390 (CCA) Serial No.: 7 (C							
INFO	RMATIO	N DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)	Applicant: James A. Williams et al.							
(37 CFR § 1.98	(b))		Filing Date: MINING HALL Group Art Unit:							
	lysis of the Clostridium difficile Toxins A and B," Molec. Gen. Genetics									
	98	Вагтоso et al. (1990) "Nucleotide Sequence of Clostridium difficile Toxin В Gene," Nucl. Acids Res. 18:4004								
	99	Thompson et al. (1990) "The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene," Eur. J. Biochem. 189:73-81								
	100	Riggs (1989) in Current Protocols in Molecular Biology, Vol.	2, Ausubei, et al. (Eds.) pp. 16.6.1-16.6.14							
	101	Schantz and Kautter (1978) "Microbiological Methods: Stand	ardized Assay for Clostridium botulinum Toxins," J. AOAC 61:96-99							
	Investigational New Drug (BB-IND-3703) application by the Surgeon General of the Department of the Army to the Federal Fo									
	103	Pearson (1985) Pyrogens: endotoxins, LAL testing and depyr	ogentaion, Marcel Dekker, NY, pp. 23-56							
	104	Smith and Corcoran (1994) *Expression and Purification of G Biology, Supplement 28:16.7.1-16.7.7	lutathione-S-Transferase Fusion Proteins," Current Protocols in Molecular							
	105	Gragerov et al. (1992) "Cooperation of GroEL/GroES and Dracoli,"Proc. Natl. Acad. Sci. USA 89:10341-10344	aK/DnaJ heat shock proteins in preventing protein misfolding in Escherichia							
	106	Fujii et al. (1990) "The Nucleotide and Deduced Amino Acid Sequences of EcoRI Fragment Containing the 5'-Terminal Region of Clostridium botulinum Type E Toxin Gene Cloned from Mashike, Iwanai and Otaru Strains," Microbiol. Immunol. 34:1041-1047								
	107	Kimura et al. (1990) "The Complete Nucleotide Sequence of the Gene Coding for Botulinum Type C ₁ Toxin in the C-St Phage Genome," Biochem. Biophys. Res. Comm. 171:1304-1311								
	108	Sunagawa et al. (1992) "The Complete Amino Acid Sequence Sequence Analysis of the Encoding Phage d-16¢ Genome," J.	of the Clostridium botulinum Type D Neurotoxin, Deduced by Nucleotide Vet. Med. Sci. 54:905-913							
	109	Binz et al. (1990) "Nucleotide sequence of the gene encoding	Clostridium botulinum neurotoxin type D," Nucleic Acids Res. 18:5556							
	Campbell et al. (1993) "Nucleotide sequence of the gene coding for Clostridium botulinum (Clostridium argentinense) type G neugenealogical comparison with other clostridial neurotoxins," Biochim. Biophy. Acta 1216:487-491									
	111	Classifier Folk Micro Letters 96:225-230								
	112	Niemann (1992) "Clostridial Neurotoxins - Proposal of a Common Nomenclature," Toxicon 30:223-225 Food and Drug Administration Document (Docket No. 79D-0465) 53 FR 5044, February 19, 1988								
	113									
	114	Food and Drug Administration Document (Docket No. 79D-0465) 48 FR 27835, June 17, 1983								
Examiner:			Date Considered:							
EXAMINER:	[ni	tial citation considered. Draw line through citation if not in corth next communication to applicant.	formance and not considered. Include copy of this form							

Sheet .L of Q

Form PTO-1449					Docket Number: 5-2939CIPCON Application Number: MA							
INFORMATION DISCLOSURE CITATION					Applicant: Williams et al.							
IN AN APPLICATION (Use several sheets if necessary)							Filing Date: MANISTH	Group Art Unit:				
						U. S. P	ATEN	IT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	RVLI	RULING DATE	
									 	 	T APP	PROPRIATE
											 	
										y	 	
										;		
	· ·								1		 	
									1		 	
												····
				·			·					
					-							
	,				FC	ORFIGN	ΡΔΤΙ	ENT DOCUMENTS			<u> </u>	
		DOC	UMENT NU	MBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
								· ·			YES	МО
			-					,				
	·		+						ļ			
			1		-							
					L	OTU	EP D	DCUMENTS	٠			·
		Diotkin .		/!	<u>*</u>							
								W.B. Saunders Compa		delphia, p.	571 (1	988)
	\dashv	Nygren,	РА.	Et al.	Tren	nds in B	ioteci	nnology 12(5): 184-1	88	· · ·	 :	
ŀ		·										
					·						·	
ļ		·									_	
EXAMIN	ER							DATE CONSIDERED				
EXAMINER	R: Initia	I if citation con	sidered, wh	ether or n	ot citati	on is in conf	iormance	with MPEP § 609; Draw line throug	nh citation if	at in conference		
Include copy of	of this fo	rm with next o	ommunicat	on to the	applican	1t.		ar a coo, olan mie tinou	, enauon n M	comormance a	ma not con:	siuareo.